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2ABSTRACT
Purpose: We herein describe the clinical course of a consecutive series of 
fulminant hepatic failure patients treated with molecular adsorbent recirculating 
system, a cell-free albumin dialysis technique.   
From November 2000 to September 2002, 7 adult patients age 22-61 (median 41), 
one male (14.2%), and 6 females (85.7%), affected by fulminant hepatic failure,
underwent 7 courses (1 to 5 session each, six hours in duration) of extracorporeal 
support using the molecular adsorbent recirculating system technique.  Pre and 
post treatment blood glucose, liver function tests, ammonia, arterial lactate, 
electrolytes, hemodynamic parameters, arterial blood gases, liver histology, 
Glasgow Coma Scale, and coagulation studies, were reviewed.  No adverse side 
effects like generalized bleeding on non-cardiogenic pulmonary edema, often seen
during MARS treatment, occurred in the patients included in this study. 
Results: Six patients (85.7%) are currently alive and well, and one (14.2%) died.  
Four patients (57%) were successfully bridged (two patients in 1 day and two 
other patients in 4 days) to liver transplantation, while 2 (28.5%) recovered fully 
without transplantation.  All the measured variables stabilized after molecular 
adsorbent recirculating system commencement.  No differences were noted 
between the pre and post molecular adsorbent recirculating system liver histology.  
3Conclusions: Molecular adsorbent recirculating system is a safe, temporary life 
support mechanism for patients awaiting liver transplantation or recovering from
fulminant hepatic failure.
Key words: Albumin, dialysis, extracorporeal liver assist device, 
fulminant hepatitis
4INTRODUCTION
Molecular adsorbent recirculating system (MARS) (Teraklin, Aktiengesellschaft, 
Rostok, Germany) is an artificial liver support system, first introduced into 
clinical practice in 1993 [1].  In contrast to bio-artificial liver support systems, 
which replace some of the metabolic and synthetic functions of the liver by 
means of established hepatocyte or hepatoblastoma cell lines [2], MARS aims 
only at clearing the blood from metabolic waste products normally metabolized 
by the liver.  It is, essentially, a modified dialysis system, employing an albumin-
containing dialysate that is recirculated and perfused in-line through charcoal and 
anion exchanger columns. This effects the removal of albumin-bound toxins like 
aromatic amino acids and their metabolites, conjugated bilirubin, bile acids, 
phenols, short and middle chain fatty acids, copper, mercaptans, cytokines, 
tryptophan, tumor necrosis factor-, interleukin-6, and diazepam together with 
free solutes like ammonia, creatinine, urea that are removed by standard dialysis 
[1, 3].  Most of the experience with MARS has shown specific efficacy in the 
treatment of acute-on-chronic hepatic failure, where it improves cerebral blood 
flow, hemodynamic status, liver and renal function, survival [4-6], and intractable 
pruritus [7].  Molecular adsorbent recirculating system maintains electrolytes 
homeostasis [8] may worsen coagulopathy [9] and be the cause non-cardiogenic 
pulmonary edema [10].   
5Fulminant hepatic failure (FHF) is defined as acute encephalopathy and 
coagulopathy in the setting of acute liver disease where altered mental status 
develops within 8 weeks from the onset of the illness in a person without 
antecedent liver disease [11].  Mortality rate in course of acute liver failure  is 
reported to be greater than 70% [12-13].  Liver transplantation (LTx) is a well 
accepted therapy for FHF [14].  However, due to lack of organ availability it is 
not always possible to transplant patients with FHF.  Therefore, several different 
types of supporting systems (artificial liver/bio-artificial liver) have been 
developed to bridge these patients to LTx or, if possible promote spontaneous 
recovery [2, 15-20].
Molecular adsorbent recirculating system has been used in course of FHF [21]; 
however, changes in liver histology and its correlation with Glasgow Coma Scale 
(GCS) and prothrombin time, the two major clinical indicator of disease 
progression, have not been addressed before. 
Fulminant hepatic failure is characterized by several biochemical derangements 
such as acidosis [12], hypophosphatemia, and hypoglycemia [22].  The degree of 
these derangements is, at least theoretically, related to the grade of liver necrosis.  
Trans-jugular liver biopsy is the method of choice to obtain liver tissue for 
histology in patients with FHF and to quantitate the degree of liver injury [23]. 
6METHODS
Data were retrospectively collected from a consecutive series of patients admitted 
at the Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione
Palermo-Italy, from November 2000 to September 2002, with FHF who
underwent MARS while awaiting LTx or recovery.  Follow-up: 1155 days, range 
455-1155 days.  Informed consent, for MARS treatment and LTx, was obtained 
from next of kin.
Seven adult patients (numbered #1 to #7), one male (14.2%) and 6 females 
(85.7%), age 22 – 61 years (median 41 years), underwent 7 courses (1 to 5 session 
each) of MARS.  Demographics are shown in Table 1.  
Patient #1 developed fulminant hepatitis B.  The patient was emergently 
transported to our center in stage 4 coma (Fig. 1) and died of brain herniation a 
few hours before LTx.  
Hepatitis B Virus (HBV) was the cause of FHF in patient # 2.  The patient was 
emergently transported to our center in stage 3 coma (Fig. 1) and underwent the 
first LTx 5 days after the admission.  The patient developed primary-non-function 
and 2 days later was successfully re-transplanted.  She is alive and well 38 months 
after the second LTx.    
Patient # 3 developed drug related (nimesulide) FHF.  The patient was emergently 
transported to our center awake and alert but 24 hours later went on to stage 3 
7coma (Fig. 1). She was successfully transplanted 2 days following admission to 
our facility.  She is alive and well 24 months after LTx.
Patient # 4 developed HBV related FHF.  The patient was emergently transported 
to our center awake and alert and remained so, despite 95% of liver necrosis, until 
the transplant, which occurred 2 days after the admission.  This patient is alive 
and well 23 months after LTx.  
Patient # 5 developed HBV related FHF.  The patient was emergently transported 
to our center in stage 3 coma, underwent two LTx during the same procedure, 5 
days after the admission.  The first graft, a very marginal one, accepted on an 
emergency base, underwent primary-non-function immediately after reperfusion, 
with about 80% hepatocyte necrosis.  A second cadaveric donor became available 
at the time of the reperfusion of the first graft.  She was, therefore, immediately 
re-transplanted.  She is alive and well 18 months after LTx.
Patient # 6 developed HBV related FHF.  She underwent 4 MARS treatments 
before showing clinical recovery from the acute event.  Due to her dramatic 
clinical improvement following the first MARS treatment and despite 50% 
necrosis at the trans-jugular liver biopsy a decision was taken not to proceed with 
the transplant.  She is alive and well 16 months after the last MARS session.
Patient # 7 developed HBV related FHF.  He was never placed on the waiting list 
for LTx because he was diagnosed with colon cancer 12 months prior to his 
evaluation.  The patient was emergently transported to our center in stage 3 coma 
8and underwent a total of 5 MARS treatments before showing clinical 
amelioration.  He is alive and well 15 months after the last MARS session.
Our pre-transplant work-up includes trans-jugular liver biopsy for those patients
fulfilling the O’Grady criteria for FHF [11] at the hospital presentation.  In fact 
emergent listing for LTx and treatment with MARS, while waiting for LTx, was 
prompted for those patients showing 50% or more liver necrosis at liver 
histology.
Exclusion criteria from MARS and/or LTx candidacy were culture-proven sepsis
and/or < 50% liver necrosis.  In the intensive care unit, before starting MARS,
full patient monitoring was instituted including: central venous pressure, Swan-
Ganz catheter placement, and systemic arterial line. Due to onsite unavailability 
of technical expertise in positioning epidural probes for intracranial pressure 
monitoring, this parameter was not followed.
Each course of MARS was intended to consist of seven treatment sessions, six 
hours in duration (none of them had to be terminated in advance), on consecutive 
days.  However, none of the patients completed the prescribed course (7 sessions)
due to transplantation, death or significant clinical improvement.  If a liver 
became available while the patient was on MARS, the transplant was started after 
the 6 hours session was completed.
9Molecular adsorbent recirculating system was performed through a hemodialysis 
double-lumen catheter, as previously described [24].  Priming of the 
extracorporeal circuit with heparinized saline solution (1,000 U of heparin 
sulphate / liter) was carried out before MARS commencement. The 
extracorporeal blood circuit was driven by a standard dialysis machine (D-85716, 
Baxter, Unterschleibheim, Germany) at a flow rate of 100 ml/min initially, 
increased to 200 ml/min if the patient remained hemodynamically stable.
The aim of this study was the assessment of the safety and efficacy of MARS in 
patients with FHF.  
During MARS therapy all patients were closely monitored for disturbances in 
electrolytes, glucose level, coagulation, and blood gas exchanges. These
derangements, if present, were treated as indicated.  
Pre and post-MARS blood glucose, liver function tests (total bilirubin, aspartate 
aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase), 
ammonia, arterial lactate, electrolytes (sodium, potassium, chloride, calcium, 
phosphorus, and magnesium as well as the ionized fraction of calcium and 
magnesium), hemodynamic parameters (systemic blood pressure, central venous 
pressure, pulmonary arterial pressures, cardiac output, cardiac index, systemic 
vascular resistance index), arterial blood gas, GCS, and coagulation studies 
(platelet count, prothrombin time, international standardized ratio), were used for 
comparison.  
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Liver histology was used to quantitate the percentage of necrosis. Post-MARS 
liver histology on the native liver, obtained at the time of LTx, and percutaneous 
liver biopsies, performed after recovery from the acute event for patients # 6 and 
# 7 (those recovered without LTx), was used for comparison with pre-MARS 
liver histology.  Patient # 1 died before transplantation, autopsy consent was 
denied; therefore, post-MARS liver histology for patient #1 was not available for 
this study.  
Data are presented as mean ± standard deviation.  Blood samples for laboratory 
tests were collected immediately before and immediately after each MARS 
session.  
RESULTS
Six patients (85.7%) survived to be discharged from the hospital and they are all 
alive and well 15 months after the last MARS session.  One patient (14.2%) died 
of brain herniation while our team was recovering a liver from an organ donor.  
Four patients (57%) were successfully bridged, using MARS, to LTx, and 2 
(28.5%) recovered fully without transplantation.  
Biochemical effect of MARS
Pre and post MARS serum electrolytes concentration remained remarkably stable 
(data not shown).  
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Hypoglycemia is common in FHF being due to altered gluconeogenesis in the 
failing liver with inadequate hepatic uptake of insulin, heading to increased 
peripheral insulin levels [22].  In our series patients treated with MARS showed 
remarkable stable blood glucose during treatments (data not shown).
Total bilirubin (Tab. 2), transaminases, gamma-glutamyl transpeptidase, and 
ammonia, as previously reported [1, 3], all improved with MARS (data not 
shown).  
Molecular adsorbent recirculating system reduced, in FHF, the arterial blood 
lactate level (Fig. 2).  
Effect of MARS on mental status
Those patients that recovered fully without LTx (patients # 6, and 7 of table 1) 
showed a steady improvement in GCS after each MARS sessions (Fig. 1).  Patient 
# 5 of table 1, also, had a significant improvement in GCS after the first MARS 
session (Fig. 1); however, at the time of LTx liver necrosis was > 95% (Tab. 3).
Hemodynamic effect of MARS
Patients with FHF tend to be hemodynamically unstable with a low systemic 
vascular resistance index and a hyperdinamic circulation [30]. None of the 
patients treated in our series, required vasopressors infusion before transplantation 
and all remained hemodynamically stable throughout MARS treatment.  
Amelioration of the hyperdynamic state, was supported by elevation of systemic 
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vascular resistance index, mean arterial pressure, and reduced cardiac index (Fig. 
3).
Effect of MARS on gas exchange
Pre and post MARS blood gas remained remarkable stable (data not shown).  
Histological effect of MARS
No signs indicative of MARS affecting liver histology were noted when pre and 
post MARS liver specimens where compared in the patients who underwent LTx 
(Tab. 3: comparison is between histology at the time of the trans-jugular liver 
biopsy and histology on the explanted liver). Four out of 5 patients who 
underwent LTx showed at the trans-jugular liver biopsy 80% or more liver 
necrosis (Tab. 3).  Patients # 6 and # 7 (those recovered without LTx) showed 50 
% liver necrosis at the admission to the hospital and absence of necrosis at 
recovery following the last MARS treatment (Tab. 3).     
Effect of MARS on blood coagulations
All patients were coagulophatic at admission and remained as such, despite 
aggressive medical correction throughout the stay in the intensive care unit, which 
consisted in continuous infusion of fresh frozen plasma at the rate of 30 cc/h.  
Although one could postulate that the percentage of necrotic liver tissue correlates 
directly to all the commonly seen clinical and biochemical derangements of FHF, 
we did not find any relationship between necrosis and prothrombin time (Fig.4).
Prothrombin time before and after MARS is reported in Figure 4.
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DISCUSSION
Paradoxically the major limitation for this study is the availability of LTx which 
occurs at various time after treatment commencement; therefore, causing 
difficulties in designing scientifically reproducible clinical trials.
We cannot exclude that some of our observed results, in terms of biochemical 
omeostasis/hemodynamic stability during treatment of FHF with MARS, may be 
secondary to aggressive medical management in the intensive care unit, preceding 
transplantation.  However, there are proven effects, in different model, of MARS 
ameliorating parameters not otherwise influenced by medical therapy, such as 
total bilirubin [1, 3], and blood lactate levels [24].  The liver is the principal organ 
for lactate metabolism, accounting for 50% of whole body lactate clearance and 
utilization, and hence participates in the regulation of serum lactate concentrations 
[25-26]. Moreover, in the LTx literature, with both cadaveric and living donor, it 
has been demonstrated that the rate of lactate elimination after reperfusion of the 
transplanted liver, represents one of the most sensitive and reliable indicators of 
hepatic graft function [27-29].  Therefore, we believe that the decrease lactate 
level during MARS treatment of patients with FHF indicates improvement (Fig. 
2).  It is uncertain whether, in our series, MARS is responsible for the observed 
decreased transaminases, because normalization of liver enzymes in the late phase 
of FHF is typically seen after massive liver necrosis. 
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However, it appears that the degree of liver necrosis, GCS, and timing in MARS 
commencement may play a role in the outcome of FHF.  
In patient # 5 we observed GCS improvement after MARS commencement (Fig. 
1), despite ongoing liver necrosis (more then 95% in the explanted liver, table 2).  
The same was also observed in patients # 6 and # 7 (those recovered without LTx) 
(Fig. 1).  We believe that the common denominator for these three patients was
the 50% liver necrosis at the time of MARS commencement. During FHF, coma 
is the antecedent of brain herniation and the various degree of mental status 
changes observed are, in fact, strictly related to the amount of death liver cells and 
the consequent toxins load present in the blood stream [11, 22, 27]. There is
multiple evidence that MARS is able to remove those toxins [1, 3]; therefore, 
based on our data, we postulate that if MARS is started before liver necrosis 
exceeds 50%, brain herniation can be delayed.  
A common criticism to trans-jugular liver biopsy in course of FHF is that it 
represents a random liver biopsy and as such it does not reflect the real percentage 
of liver necrosis present in the whole liver.  However, 80% of the patients in our 
series who were transplanted (patients numbered 1 to 4, table 3) showed a
sensitive correlation between pre and post transplant amount of liver necrosis.  
Therefore, we believe that the percentage of liver necrosis seen at the trans-
jugular liver biopsy should be used as a clinical guidance to transplantation.  We 
did not expect any histological change after MARS because of the very few 
15
treatment sessions and the short time allowed between the histological 
observations.  For other reasons (few MARS sessions and long interval between 
histological observations) we believe that the absence of necrosis in the post-
MARS liver histology for patients # 6 and # 7 was not a consequence of MARS
treatment.  It was expression of healing from FHF.  
Obviously, each patient of our series was treated with a different number of 
MARS sessions because suitable organ donors became available at different times
during MARS treatment for the different patients.  Nonetheless, in our small 
series, MARS was found to be safe and efficacious in maintaining stability in 
patients diagnosed with FHF and awaiting LTx.  Our result suggest that MARS
delayed central nervous system catastrophe by clearing the toxins load typical of 
FHF, thus allowing more time for successful bridging to LTx.
16
REFERENCES
1. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R: A new 
procedure for the removal of protein bound drugs and toxins. ASAIO J  
39(3):M621-5, 1993
2. Jaregui HO: Cellular component of bioartificial liver support systems. Artif 
Organs 23(10):889-893, 1999
3. Mitzner SR, Stange J, Klammt S,  Risler T, Erley CM, Bader BD, Berger ED, 
Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock, J, Löhr JM, Liebe 
S, Emmrich J, Korten G, Schmidt R: Improvement of hepatorenal syndrome 
with extracorporeal albumin dialysis MARS: results of a prospective, 
randomized, controlled clinical trial. Liver Transpl 6(3):277-286, 2000
4. Sorkine P, Ben Abraham R, Szold O, Biderman P, Kidran A, Merchav H, 
Brill S, Oren R: Role of molecular adsorbent recycling system (MARS) in the 
treatment of patients with acute exacerbation of chronic liver failure. Crit 
Care Med 29(7):1332-1336, 2001
5. Schmidt LE, Svedensen LB, Sørensen VR, Hansen BA, Larsen FS: Cerebral 
blood flow velocity increases during a single treatment with molecular 
adsorbents recirculating system in patients with acute on chronic liver failure. 
Liver Transpl 7(8):709-712, 2001
6.  Schmidt LE, Sørensen VR, Svedensen LB, Hansen BA, Larsen FS:
Hemodynamic changes during a single treatment with the molecular 
17
adsorbents recirculating system in patients with acute-on-chronic liver failure. 
Liver Transpl 7(12):1034-1039, 2001
7. Doria C, Mandala` L, Smith J, Vitale CH, Lauro A, Gruttadauria S, Marino
IR, Scotti Foglieni C, Magnone M, Scott VL: Effect of MARS in HCV-
related intractable pruritus.  Liver Transpl 9(4):437-443, 2003
8. Doria C, Doyle HR, Mandala` L, Marino IR, Caruana G, Gruttadauria S, 
Lauro A, Magnone M, Scotti Foglieni C, Lamonaca V, Scott VL: Changes in 
serum electrolytes during treatment of patients in liver failure with molecular 
adsorbent recirculating system. Int J Artif Organs 26(10):918-23, 2003
9. Doria C, Mandala` L, Smith J, Caruana G, Scott VL, Gruttadauria S, 
Magnone M, Marino IR: Thromboelastography used to assess coagulation 
during treatment with molecular adsorbent recirculating system. Clin 
Transplant 2004;18:367-371.
10. Doria C, Mandala` L, Scott VL, Marino IR, Gruttadauria S, Miraglia R, 
Vitale CH, Smith J: Non-cardiogenic pulmonary edema induced by molecular 
adsorbent recirculating system. Case report. J Artif Organs 6(4):282-285, 
2003.
11. O’Grady JG, Schalm SW, Williams R: Acute liver failure: redefining the 
syndromes. Lancet 342:273-5, 1993
12. O’Grady JG, Graeme JMA, Hayllar K, Williams R: Early indicators of 
prognosis in fulminant hepatic failure. Gastroenterology 97:439-45, 1989
18
13. O’Grady JG, Gimson AES, O’Brien CJ, Pucknell A, Hughes RD, Williams 
R: Controlled trials of charcoal hemoperfusion and prognostic factors in 
fulminant hepatic failure. Gastroenterology 94:1186-92, 1988. 
14. Van Thiel DH, Brems J, Nadir A, Idilman R, Colantoni A, Holt D, Edelstein
S: Liver transplantation for fulminant hepatic failure. J Gastroenterol
37[Suppl XIII]:78-81, 2002
15. Yamazaki Z, Fujimori Y, Sanjo K, Kojimay Y, Sugiura M, Wada T, Inoue N, 
Sakai T, Oda T, Kominami N, Fujisaki U, Kataoka K: New artificial liver 
support system (plasma perfusion detoxification) for hepatic coma. 1978.
Ther Apher 4(1):23-5, 2000
16. Hughes RD, Nicolau N, Langley PG, Ellis AJ, Wendon JA, Williams R:
Plasma cytokine levels and coagulation and complement activation during 
use of the extracorporeal liver assist device in acute liver failure. J Artif 
Organs 22(10):854-858, 1998
17. Ting PP, Demetriou AA: Clinical experience with artificial liver support 
systems. Canadian Journal of Gastroenterology14[Suppl]D:79D-84D, 2000
18. Falkenhagen D, Strobl W, Vogt G, Schrefl A, Linsberger I, Gerner FJ, 
Schoenhofen M. Fractionated plasma separation and adsorption system: a 
novel system for blood purification to remove albumin bound substances.  J 
Artif Organs 23(1):81-86, 1999
19
19. Bismuth H, Figuerio J, Samuel D: What should we expect from a bioartificial 
liver in fulminant hepatic failure? J Artif Organs 22(1):26-31, 1998
20. Jalan R, Williams R: Bio-artificial liver support for acute liver failure: should 
we be using it to treat patients? Transplantation 73(2):165-166, 2002.
21. Steiner C, Mitzner S:  Experiences with MARS liver support therapy in liver 
failure: analysis of 176 patients of the international MARS registry. Liver
22(Suppl. 2):20-25, 2002
22. Lee WM: Medical progress: acute liver failure. N Engl J Med 329(25):1862-
1872, 1993
23. McAfee JH, Keeffe EB, Lee RG, Rosch J: Transjugular liver biopsy. 
Hepatology 15(4):726-32, 1992
24. Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, Klammt S, 
Peszynski P, Freytag J, Hickstein H, Löhr M, Liebe S, Schareck W, Hopt UT, 
Schmidt R: Molecular adsorbent recycling system (MARS): clinical results of 
a new membrane-based blood purification system for bioartificial liver 
support. J Artif Organs 23(4):319-330, 1999
25. Buchalter S, Crain M, Kreisberg: Regulation of lactate metabolism in vivo. 
Diabetes Metab Rev 5(4):379-391, 1989
26. Kreisberg R: Lactate homeostasis and lactic acidosis. Ann Intern Med 92(2 Pt 
1):227-237, 1980
20
27. Fath JJ, Ascher NL, Konstantinided FN, Bloomer J, Sharp H, Najarian JS, 
Cerra FB: Metabolism during hepatic transplantation: indicators of allograft 
function. Surgery 96(4):664-674, 1984
28. De Gasperi A, Mazza E, Corti A, Zoppi F, Prosperi M, Fantini G, Scaiola A, 
Colella G, Amici O, Notaro P, Rocchini A, Ceresa F, Roselli E, Grugni MC:
Lactate blood levels in the perioperative period of orthotopic liver 
transplantation. Int J Clin Lab Res 27(2):123-128, 1997
29. Orii R, Sugawara Y, Hayashida M, Yamada Y, Kubota K, Takayama T,
Harihara Y, Makuuchi M, Hanaoka K: Peri-operative blood lactate levels in 
recipients of living-related liver transplantation. Transplantation 69(10):2124-
2127, 2000
30. Hoofnagle JH, Carithers Jr RL, Shapiro C, Ascher N: Fulminant hepatic 
failure: summary of a workshop. Hepatology 21(1):240-252, 1995
21
Table 1: PATIENT AND LABORATORY DATA AT HOSPITAL ADMISSION
Footnotes:
AST: Aspartate aminotransferase. 
ALT: Alanine aminotransferase.
GT: Gamma-glutamyl transpeptidase.
PT: Prothrombin time
FHF: Fulminant Hepatic Failure
HBV: Hepatitis B Virus
N Sex/age Diagnosis Outcome/# of 
MARS 
sessions
Follow-
up days
Total 
bilirubin
mg/dl
AST
IU/L
ALT
IU/L
GT
IU/L
Albumin
gr.
PT 
%
1 F/30 FHF/HBV Died/2 0 7.41 789 2223 44 3.5 28
2 F/29 FHF/HBV Alive-
transplanted/4
820 6.97 289 1120 25 3.4 28
3 F/22 FHF/
nimesulide
Alive-
transplanted/1
393 13.13 209 254 48 3.8 30
4 F/51 FHF/HBV Alive-
transplanted/1
366 11.65 1239 1986 60 3 38.6
5 F/61 FHF/HBV Alive-
transplanted/4
218 17.01 749 1519 51 3 39.6
6 F/41 FHF/HBV Alive/4 184 9.94 455 1730 51 3.1 30
7 M/50 FHF/HBV Alive/5 180 12.08 638 2308 30 2.8 24.1
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Table 2: CHANGE IN TOTAL BILIRUBIN
Patient 
number
Pre-MARS 
total 
bilirubin 
mg/dl
Post-MARS 
session #1 
total 
bilirubin 
mg/dl
Post-MARS 
session #2 
total 
bilirubin 
mg/dl
Post-MARS 
session #3 
total 
bilirubin 
mg/dl
Post-MARS 
session #4 
total 
bilirubin 
mg/dl
1 7.41 8.48 8.91 8.14 7.31
2 6.97 8.33 7.88 6.78 6.72
3 13.13 10.06 11.29 - -
4 11.65 10.83 - - -
5 17.01 12.17 - - -
6 9.94 8.10 - - -
7 12.08 12.03 - - -
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Table 3: PRE AND POST MARS LIVER HISTOLOGY
Patient number Pre-MARS necrosis Post-MARS necrosis
1 80% n/a
2 100% (massive) 100% (massive)
3 95 % 90%
4 95% 100% (massive)
5 50% > 95% (submassive)
6 50% 0%
7 50% 0%
24
Correlation between GCS and necrosis during MARS
Figure 1 legend:
Glasgow Coma Scale is represented by bars.  The percentage of liver necrosis is 
represented by lines.  Each group of bars refers to a single patient.  The first bar, 
for each patient, identifies the pre-MARS GCS, the following bars of each group 
represent GCS after each MARS session up to three sessions.  The line with a 
triangular dot represents the percentage of liver necrosis before MARS 
commencement.  The line with the quadrate dot represent the percentage of liver 
necrosis on the explanted liver or (for patient #6 and # 7), at recovery after the 
acute event.
Footnotes:
GCS: Glasgow Coma Scale
MARS: Molecular Adsorbent Recirculating System
Pt: Patient
T: Treatment
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Pattern of arterial lactate during MARS in FHF
Figure 2 legend:
The x axis represents the mean arterial lactate concentration in mmol/L, whereas 
the y axis represents the different MARS sessions.
Footnotes:
MARS: Molecular Adsorbent Recirculating System
FHF: Fulminant Hepatic Failure
26
CO, CI and SVRI during MARS in FHF
Figure 3 legend:
Mean cardiac output and cardiac index are represented by bars of different color.  
Their unit of measure is L/min and is reported on the left side of the figure.  Mean 
systemic vascular resistance index is represented by a line.  Its unit of measure is 
dynes/cm/m2 and is reported on the right side of the figure.  The first set of bars 
represents pre-MARS values, whereas the following sets represent post-MARS 
values from session 1 to 4.
Footnotes:
CO: Cardiac output
CI: Cardiac index
SVRI: Systemic vascular resistance index
27
Correlation between PT and necrosis during MARS
Figure 4 legend:
Bars represent pre and post-MARS percentage of liver necrosis whereas lines 
indicate the prothrombin time.  The triangular dot represent pre-MARS 
prothrombin time, the X dot represent post-MARS prothrombin time.
Footnotes:
PT: Prothrombin Time
Pt: Patient
T: Treatment
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